Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 20,155

Document Document Title
WO/2019/009412A1
The present invention addresses the problem of providing a novel compound having high LSD1 inhibitory activity, high selectivity for LSD1 inhibition, and/or having useful therapeutic effects for various diseases. One embodiment of the pr...  
WO/2019/002571A1
This invention relates to compounds of formula (I) and their use as allosteric modulators of mGluR5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment and/or prev...  
WO/2019/006231A1
Provided herein is a synthesis for omecamtiv mecarbil dihydrochloride hydrate and various intermediates. (I)  
WO/2018/233326A1
A hydrogen sulfide donor in an organic salt form and a preparation method therefor. The hydrogen sulfide donor is a salt structure formed by organic compounds with an alkaline structure and hydrogen sulfide. The hydrogen sulfide donor ha...  
WO/2018/227430A1
Provided are a crystal VII-type substance of compound A (chemical name: 1-piperazine dithioformate-3-cyano-3,3-dibenzylisopropylester hydrochloric acid), the preparation method therefor, the pharmaceutical composition thereof and the use...  
WO/2018/227429A1
Provided are a crystal type II substance of a compound A (chemical name:1-piperazine dithioformate-3-cyano-3,3-diphenylpropyl ester hydrochloride, a preparation method therefor, and pharmaceutical composition and application thereof in p...  
WO/2018/229596A1
A melt additive compound has the general formula (I) wherein R represents a linear alkylene group having from 1 to 18 carbon atoms; n represents an integer from 1 to 4, inclusive; and Rf 1is represented by the general formula II wherein ...  
WO/2018/229794A1
The present invention discloses amorphous form of Cariprazine, method of manufacturing; premix of amorphous Cariprazine and pharmaceutical compositions thereof.  
WO/2018/230710A1
A lipid membrane structure contains, as a lipid component, a lipid compound represented by formula (I): (R1)(R2)C(OH)-(CH2)a-(O-CO)b-X [wherein a represents an integer of 3 to 5; b represents an integer of 0 or 1; R1 and R2 independently...  
WO/2018/232120A1
The disclosure features amino lipids and compositions involving the same. Nanoparticle compositions include an amino lipid as well as additional lipids such as phospholipids, structural lipids, PEG lipids, or a combination thereof. Nanop...  
WO/2018/224594A1
Cocrystals of vortioxetinehydrobromide and resorcinol, their preparation processes, as well as pharmaceutical compositions comprising them. The cocrystals are useful as active pharmaceutical ingredients of medicaments for the treatment o...  
WO/2018/225737A1
Provided is a catalyst for debenzylation reactions, which enables the achievement of a higher yield of a target product (a debenzylated product) in comparison to conventional Pd-supporting catalysts in a debenzylation reaction wherein a ...  
WO/2018/225018A1
The present invention relates to novel heterocyclic compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers and polymorphs. The invention also relates...  
WO/2018/218281A1
A process for inhibiting the formation of gas hydrates in a hydrocarbon fluid comprising adding to the hydrocarbon fluid, a gas hydrate anti-agglomerate which is a biodegradable anti-agglomerant derived from a naturally occurring substance.  
WO/2018/220020A2
The invention relates to resorcinol-derived compounds of formula (I) and also the salts thereof, the solvates thereof and the optical and/or geometrical isomers thereof, including enantiomers and diastereoisomers, the racemic mixtures th...  
WO/2018/216800A1
The present invention provides: a compound represented by general formula (I) or a salt thereof; an LSD1 inhibitor which contains the compound or a salt thereof as an active ingredient; a pharmaceutical composition which contains the com...  
WO/2018/214812A1
The present invention relates to a compound used as an autophagy regulator, and a preparation method therefor and uses thereof. Particularly, provided is a compound represented by general formula (I) or a pharmaceutically acceptable salt...  
WO/2018/210274A1
Provided is a novel, mild, highly effective, and economic process for co-producing formamide and monofunctional or polyfunctional acrylamide compounds.  
WO/2018/207192A1
Methods of treating leukodystrophy are provided. Accordingly there is provided a method of treating leukodystrophy in a subject, the method comprising administering to the subject a therapeutically effective amount of an agent capable of...  
WO/2018/197324A1
The present invention refers to a process for reacting an alkyl aryl ketone obtaining thereby the corresponding aryl oxirane or α-functionalized alkyl aryl ketal, the aryl oxirane or α-functionalized alkyl aryl ketal obtained by the pr...  
WO/2018/197325A1
The present invention refers to a process for the preparation of an α-functionalized ketone, an α-functionalized ketone obtained by said process, a photopolymerizable composition comprising the α-functionalized ketone and at least one...  
WO/2018/196860A1
The present invention relates to the field of chemical synthesis, and in particular to an ammonium carboxylate compound, a crystal form and an amorphous substance thereof, and a preparation method therefor. The present invention prepares...  
WO/2018/197360A1
A process for the manufacture of vortioxetine HBr α-form is provided.  
WO/2018/193297A1
The present invention provides compounds which are modulators of RORϒ and their use for the treatment of diseases or conditions mediated by RORϒ. Further, the present invention relates to processes of preparing such compounds, their ta...  
WO/2018/194976A1
Methods of reducing neuronal sensitivity, thereby reducing inflammation and chronic pain, are disclosed herein. Particularly disclosed are methods of administrating the apurinic/apyrimidinic endonuclease 1 redox factor 1 (APE1/Ref-1) inh...  
WO/2018/192323A1
Disclosed are applications of spermidine and its derivative. Based on existing protein structure data and small molecular data, the inventor performs screening by means of software-based computational analysis to obtain compounds that ca...  
WO/2018/187740A1
Cyclooctene conjugates of therapeutic or diagnostic agents have improved aqueous solubility and can release the agents upon contact with a tetrazine-containing biomaterial. The cyclooctene conjugates provide site-selective delivery of ag...  
WO/2018/186365A1
The present invention relates to a novel read-through inducing agent, and also relates to a compound represented by general formula (I) (symbols in the formula are as described in the specification) or a pharmaceutically accepted salt th...  
WO/2018/181884A1
The objective of the present invention is to provide a novel compound inhibiting the entry of a filovirus into a cell, a medical composition, an anti-filovirus agent, or a filovirus entry inhibitor containing the compound, as well as a m...  
WO/2018/182639A1
The present disclosure relates to methods of transitioning patients or obese patients being treated with vortioxetine to treatment with a monoamine oxidase inhibitor (MAOI). The methods provided include delaying administration of the MAO...  
WO/2018/178142A1
The present invention is directed to crystalline salt of 5-methyl-(6S)-tetrahydrofolic acid comprising (i) 5-methyl-(6S)-tetrahydrofolic acid, (ii) sodium and (iii) an organic base having a pKa value from 6 to 11; wherein the molar ratio...  
WO/2018/172696A1
The invention relates to ionic liquids comprising the association of a cation of the following formula (I), in which -R1 is an acyclic hydrocarbonated group, n is a whole number between 0 and 3, and m is a whole number between 1 and 4, a...  
WO/2018/165718A1
This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, PCSK9, or a pharmaceutically acceptable salt, solvate, prodrug or polymorph thereof, and to compositions and ...  
WO/2018/170306A1
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions fu...  
WO/2018/166938A1
The invention pertains to a process for preparing hydroxyethylethyleneamines, ethyleneamines, or mixtures thereof, and/or ethylene urea derivatives thereof comprising the step of reacting diethanolamine with an amine-functional compound ...  
WO/2018/169880A1
Provided herein are compounds and pharmaceutical compositions comprising said compounds useful as modulators of MAGL and/or FAAH. The subject compounds and compositions are useful for the treatment of pain and neurological disorders.  
WO/2018/169642A1
An adhesive article includes a pressure-sensitive adhesive layer with a release liner releasably adhered thereto. The release liner comprises a thermoplastic polymer and a first release agent represented by the formula: Each R1 represent...  
WO/2018/161476A1
The present invention relates to the field of pharmaceutical chemistry. Provided are an amide compound and a preparation method and use thereof. The compound can inhibit cancer cell proliferation, thereby treating a cancer. Particularly,...  
WO/2018/159827A1
The present invention provides a novel non-steroid-type compound or a salt thereof, having BR-like activity which is useful for regulating plant growth, an agricultural composition containing the compound or the salt thereof, and uses th...  
WO/2018/154451A1
The present invention is related to an improved process for the preparation and purification of crystalline polymorph of Vortioxetine hydrobromide of Formula-I and Vortioxetine hydrochloride of Formula-Ia. The process according to presen...  
WO/2018/151633A1
The present invention relates to a method for producing a compound of formula I, where B is, independently, hydrogen or [see appropriate figure], wherein no more than one B is hydrogen; D is NR1 or O; R1 is H, R, C1-C4 alkyl, unsubstitut...  
WO/2018/150344A1
The invention relates to vortioxetine hydrobromide having particle size distribution of D98 100-200μ, D50 35-90μ and D5 7-30μ as well as to a stable, reproducible and bioequivalent pharmaceutical composition comprising vortioxetine hy...  
WO/2018/150906A1
This liquid crystal display device 10 is provided with: a pair of substrates which have conductive films 14, 15, respectively; a liquid crystal layer 12 which is arranged between the pair of substrates and contains liquid crystals; and a...  
WO/2018/149991A1
The present invention relates to particular sulfonamide derivatives, the pharmaceutically acceptable addition salts thereof, the hydrates thereof and/or the solvates thereof, and also the use thereof as inverse agonists of retinoid-relat...  
WO/2018/138359A1
The present invention provides novel compounds of formula (la) that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of R...  
WO/2018/140512A1
Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): (I) or a pharmaceutically acceptable salt, isotopic form, stereoisomer or prodrug thereof, wherein A, B, X,...  
WO/2018/138354A1
The present invention provides novel compounds of formula (la) that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of R...  
WO/2018/139326A1
Provided are: a friction-reducing agent containing neither sulfur nor phosphorus and having excellent friction-reducing properties; and a lubricating oil composition containing the friction-reducing agent. The friction-reducing agent com...  
WO/2018/134695A1
The present invention provides, in part, compounds of Formula (I) and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or sa...  
WO/2018/136792A1
The present disclosure provides compounds and methods for inhibiting or degrading the N-terminal domain of the androgen receptor, as well as methods for treating cancers such as prostate cancer.  

Matches 1 - 50 out of 20,155